MNPR
NASDAQMonopar Therapeutics Inc.
News · 26 weeks49-30%
2026-03-012026-08-23
Mix2990d
- SEC Filings15(52%)
- Other5(17%)
- Insider5(17%)
- Leadership3(10%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- PRMonopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for the treatment of Wilson disease, have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place November 5-9, 202
- ANALYSTMonopar Therapeutics downgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald downgraded Monopar Therapeutics from Overweight to Neutral and set a new price target of $119.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form 10-Q filed by Monopar Therapeutics Inc.10-Q - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesWILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates. Recent Program Developments ALXN1840 for Wilson Disease – Rolling NDA Submission Initiated On July 22, 2026, Monopar announced it had initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALXN1840. The FDA authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 filed by Monopar Therapeutics Inc.S-8 - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form S-8 POS filed by Monopar Therapeutics Inc.S-8 POS - Monopar Therapeutics (0001645469) (Filer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Initiates Rolling NDA Submission for ALXN1840 in Wilson DiseaseWILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex ("ATC") activator for the treatment of Wilson disease. The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the
- PRMonopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership TeamWILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company’s first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, was elected to the Board of Directors at the Company’s Annual Meeting of Stockholders on June 22, 2026. In addition, Monopar has appointed Sharon Funk as Senior Vice President, Sales
- SECAmendment: SEC Form 144/A filed by Monopar Therapeutics Inc.144/A - Monopar Therapeutics (0001645469) (Subject)
- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- INSIDERChief Financial Officer Vu Quan Anh converted options into 1,228 shares and covered exercise/tax liability with 507 shares, increasing direct ownership by 48% to 2,221 units (SEC Form 4) (for withholding tax)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Executive Officer Robinson Chandler converted options into 12,873 shares and covered exercise/tax liability with 4,084 shares, increasing direct ownership by 10% to 99,267 units (SEC Form 4) to satisfy withholding obligation4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Operating Officer Cittadine Andrew converted options into 5,254 shares and covered exercise/tax liability with 2,309 shares, increasing direct ownership by 6% to 55,614 units (SEC Form 4) to satisfy tax liability4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 4 filed by Director Sweeny Nicole4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sweeny Nicole3 - Monopar Therapeutics (0001645469) (Issuer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson DiseaseWILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company’s late-stage candidate for the treatment of Wilson disease. The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth to 18 years of age. The designation provides the Company with the potential at the time of
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
MNPR FAQ
7 questionsWhat does Monopar Therapeutics Inc. do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a...Where does MNPR stock trade?
Monopar Therapeutics Inc. (MNPR) is listed on NASDAQ.What sector and industry is MNPR in?
Monopar Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Monopar Therapeutics Inc. go public?
Monopar Therapeutics Inc. (MNPR) completed its IPO in 2019.What are analysts saying about MNPR?
Monopar Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Neutral on 2026-08-13.What companies are similar to MNPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MNPR side-by-side with any of them on Quantisnow.How can I track MNPR on Quantisnow?
Quantisnow aggregates Monopar Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNPR to receive live email and push alerts on every new disclosure.